<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02557412</url>
  </required_header>
  <id_info>
    <org_study_id>PINML01</org_study_id>
    <nct_id>NCT02557412</nct_id>
  </id_info>
  <brief_title>Effect of Nasal CPAP on Lipid Profile in Patients With Dyslipidaemia and Sleep Apnea</brief_title>
  <official_title>Long-term Effect of Nasal Continuous Positive Airway Pressure on Lipid Profile in Patients With Dyslipidaemia and Mild-moderate Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Principe de Asturias</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES Main objective: To assess if six months of treatment with CPAP, associated with&#xD;
      conventional treatment, improves the lipid profile of patients with dyslipidemia and&#xD;
      mild-moderate apnea-hypopnea syndrome (OSA).&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  Determine the additional effect of CPAP on insulin resistance and dyslipidemia in&#xD;
           patients with mild-moderate OSA.&#xD;
&#xD;
        -  Assess the impact of CPAP treatment in reducing cardiovascular risk in patients with&#xD;
           dyslipidemia and mild-moderate OSA.&#xD;
&#xD;
      DESIGN Randomized, parallel group, non-blind, controlled clinical trial with conventional&#xD;
      treatment.&#xD;
&#xD;
      STUDY POPULATION 35-75 year old subjects, diagnosed with dyslipidemia in last six months and&#xD;
      in stable treatment during the last month with diet, cholesterol lowering drug, and&#xD;
      cholesterol LDL levels&gt; 100 mg / dl in the last two successive visits clinics.&#xD;
&#xD;
      Sample size. 38 patients who completed the test in each treatment arm.&#xD;
&#xD;
      TREATMENT&#xD;
&#xD;
      Patients will be randomized to one of the following treatment arms form:&#xD;
&#xD;
        1. hygiene and dietary recommendations.&#xD;
&#xD;
        2. lifestyle intervention (more strict and promotion of daily physical activity and dietary&#xD;
           control).&#xD;
&#xD;
        3. Treatment with positive airway pressure (CPAP).&#xD;
&#xD;
      ENDPOINTS:&#xD;
&#xD;
      Efficacy endpoints.&#xD;
&#xD;
        -  Primary endpoint: LDL-cholesterol.&#xD;
&#xD;
        -  Total cholesterol, HDL-cholesterol, triglycerides and C-reactive protein high&#xD;
           sensitivity (hsCRP).&#xD;
&#xD;
        -  Systemic Biomarkers: inflammatory (IL-6, IL-8 and tumor necrosis factor (TNF)-α),&#xD;
           oxidative stress (8-isoprostane), endothelial damage (endothelin, vascular cell adhesion&#xD;
           molecule 1 (VCAM-1) and Intercellular Adhesion Molecule 1 (ICAM-1)), sympathetic&#xD;
           activity (neuropeptide Y) and appetite-regulating hormones (leptin, orexin A /&#xD;
           hypocretin-1 and ghrelin).&#xD;
&#xD;
        -  Fasting glucose, glycated hemoglobin (HbA1c), fasting insulin and Homeostasis Model&#xD;
           Assessment (HOMA) index and quantitative insulin sensitivity check index (QUICKI),&#xD;
           thyroid-stimulating hormone (TSH).&#xD;
&#xD;
        -  Clinical questionnaires: short-form (SF)-12, EuroQoL, Functional Outcomes of Sleep&#xD;
           Questionnaire (FOSQ) and International physical activity questionnaire (IPAQ).&#xD;
&#xD;
      Security endpoints.&#xD;
&#xD;
        -  Notification of clinical adverse events.&#xD;
&#xD;
        -  Compliance with CPAP (average hours use per day).&#xD;
&#xD;
        -  Epworth Sleepiness Questionnaire.&#xD;
&#xD;
        -  Development of cardiovascular events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES&#xD;
&#xD;
      Main objective: To assess if six months of treatment with CPAP, associated with conventional&#xD;
      treatment, improves the lipid profile of patients with dyslipidemia and mild-moderate&#xD;
      apnea-hypopnea syndrome (OSA).&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  Determine the additional effect of CPAP on insulin resistance and dyslipidemia in&#xD;
           patients with mild-moderate OSA.&#xD;
&#xD;
        -  Assess the impact of CPAP treatment in reducing cardiovascular risk in patients with&#xD;
           dyslipidemia and mild-moderate OSA.&#xD;
&#xD;
        -  Analyze the impact of supplemental CPAP treatment on glycemic control and the&#xD;
           concentration of hsCRP in patients with dyslipidemia and mild-moderate OSA.&#xD;
&#xD;
        -  Establish the impact of supplemental CPAP treatment on quality of life related to health&#xD;
           of patients with dyslipidemia and mild-moderate OSA.&#xD;
&#xD;
        -  Evaluate the effect of CPAP on inflammatory cytokines, oxidative stress biomarkers,&#xD;
           sympathetic tone and regulating hormones intake in patients with dyslipidemia and&#xD;
           mild-moderate OSA.&#xD;
&#xD;
        -  Correlate CPAP induced changes in lipid levels with the changes produced in the basal&#xD;
           inflammatory response, oxidative stress, sympathetic activity and intake regulating&#xD;
           hormones.&#xD;
&#xD;
        -  Compare the effect of CPAP with promotion of daily physical activity on lipid profile in&#xD;
           patients with dyslipidemia and mild-moderate OSA.&#xD;
&#xD;
        -  Identify the subgroup of patients with uncontrolled dyslipidemia and mild-moderate OSA&#xD;
           in wich six months of treatment with CPAP achieve a more pronounced reduction in blood&#xD;
           lipids.&#xD;
&#xD;
      DESIGN Randomized, parallel group, non-blind, controlled clinical trial with conventional&#xD;
      treatment.&#xD;
&#xD;
      STUDY POPULATION 35-75 year old subjects, diagnosed with dyslipidemia in last six months and&#xD;
      in stable treatment during the last month with diet, cholesterol lowering drug, and&#xD;
      cholesterol LDL levels&gt; 100 mg / dl in the last two successive visits clinics.&#xD;
&#xD;
      Sample size. 38 patients who completed the test in each treatment arm.&#xD;
&#xD;
      TREATMENT&#xD;
&#xD;
      Patients will be randomized to one of the following treatment arms form:&#xD;
&#xD;
        1. hygiene and dietary recommendations.&#xD;
&#xD;
        2. lifestyle intervention (more strict and promotion of daily physical activity and dietary&#xD;
           control).&#xD;
&#xD;
        3. Treatment with positive airway pressure (CPAP).&#xD;
&#xD;
      ENDPOINTS Efficacy endpoints.&#xD;
&#xD;
        -  Primary endpoint: LDL-cholesterol.&#xD;
&#xD;
        -  Total cholesterol, HDL-cholesterol, triglycerides and C-reactive protein high&#xD;
           sensitivity (hsCRP).&#xD;
&#xD;
        -  Systemic Biomarkers: inflammatory (IL-6, IL-8 and TNF-α), oxidative stress&#xD;
           (8-isoprostane), endothelial damage (endothelin, VCAM-1 and ICAM-1), sympathetic&#xD;
           activity (neuropeptide Y) and appetite-regulating hormones (leptin, orexin A /&#xD;
           hypocretin-1 and ghrelin).&#xD;
&#xD;
        -  Fasting glucose, glycated hemoglobin (HbA1c), fasting insulin and HOMA and QUICKI&#xD;
           indexes, TSH.&#xD;
&#xD;
        -  Clinical questionnaires: SF-12, EuroQoL, FOSQ and IPAQ.&#xD;
&#xD;
      Security endpoints.&#xD;
&#xD;
        -  Notification of clinical adverse events.&#xD;
&#xD;
        -  Compliance with CPAP (average hours use per day).&#xD;
&#xD;
        -  Epworth Sleepiness Questionnaire.&#xD;
&#xD;
        -  Development of cardiovascular events.&#xD;
&#xD;
      STATISTICAL PROCEDURES Data will be expressed as mean ± standard deviation, median&#xD;
      (interquartile range) or percent, depending on type and distribution. For comparison between&#xD;
      groups, or t-Student test, or the Mann-Whitney U-test or chi-square test will be used, as&#xD;
      appropriate. The relationships between variables will be analyzed by Pearson correlation and&#xD;
      multiple linear regression.&#xD;
&#xD;
      The treatment effect will be evaluated by analysis of variance for repeated measures with&#xD;
      post-hoc multiple comparisons, using the Bonferroni test. A model of multiple logistic&#xD;
      regression will be applied to determine the variables associated with treatment response. P&#xD;
      values will be considered statistically significant &lt;0.05.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Limitations to recruitment related to COVID&#xD;
  </why_stopped>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-cholesterol</measure>
    <time_frame>6 months</time_frame>
    <description>LDL-cholesterol level in peripheral blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>6 months</time_frame>
    <description>Total cholesterol, HDL-cholesterol, and triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic biomarkers</measure>
    <time_frame>6 months</time_frame>
    <description>C-reactive protein, IL-6, IL-8, TNF-α, 8-isoprostane, endothelin, VCAM-1, ICAM-1, neuropeptide Y, leptin, orexin and ghrelin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin</measure>
    <time_frame>6 months</time_frame>
    <description>Glycated hemoglobin (HbA1c).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>6 months</time_frame>
    <description>HOMA and QUICKI indexes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>SF-12, EuroQoL and FOSQ questionnaires (generic and specific health-related quality of life).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily physical activity</measure>
    <time_frame>6 months</time_frame>
    <description>IPAQ questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical adverse events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CPAP compliance</measure>
    <time_frame>6 months</time_frame>
    <description>Mean of CPAP use per night (h/night)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleepiness</measure>
    <time_frame>6 months</time_frame>
    <description>Epworth Sleepiness Scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Sleep Apnea</condition>
  <condition>Dyslipidaemia</condition>
  <arm_group>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Hygiene and diet recommendations on sleep.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive lifestyle intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lifestyle intervention will consist of a structured intervention in a specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% [saturated fats &lt;7% monounsaturated fats up to 20% and polyunsaturated fats &lt;10% ] and proteins: 15-20%), which will be repeated in each review. Also, be recommended to increase daily physical activity, setting a target walking 10,000 steps a day. To do this, to patients assigned to this treatment arm, will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous positive airway pressure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with nasal continuous positive airway pressure (CPAP). Treatment begins with an empirical pressure of 8 centimetres of water (cmH2O) and in a period of three weeks, the pressure is adjusted by titration with an automatic positive airway pressure device (AutoSet II, ResMed).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous positive airway pressure</intervention_name>
    <description>Treatment with nasal CPAP. Treatment begins with an empirical pressure of 8 cmH2O and in a period of three weeks, the pressure is adjusted by automatic titration with AutoSet II (ResMed) device.</description>
    <arm_group_label>Continuous positive airway pressure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intensive lifestyle intervention</intervention_name>
    <description>Specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% [saturated fats &lt;7% monounsaturated fats up to 20% and polyunsaturated fats &lt;10% ] and proteins: 15-20%) and recommendation to increase daily physical activity, setting a target walking 10,000 steps a day. The patients will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.</description>
    <arm_group_label>Intensive lifestyle intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional treatment</intervention_name>
    <description>Hygiene and diet recommendations on sleep</description>
    <arm_group_label>Conventional treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of dyslipidemia: The existence of a previous clinical diagnostic of&#xD;
             dyslipidemia associated with lipid-lowering therapy. It is also considered patients&#xD;
             who have an altered analytical, using the following cutoffs: total cholesterol ≥ 200&#xD;
             mg / dl, triglycerides ≥ 180 mg / dl, HDL-cholesterol ≤ 40 mg / dl or LDL-cholesterol&#xD;
             ≥ 150 mg / dl. Lipid-lowering treatment and diet, stable in the last month.&#xD;
&#xD;
          -  A concentration of LDL-cholesterol above 100 mg / dl, in the month prior to inclusion.&#xD;
&#xD;
          -  An apnea-hypopnea index between 5-30 h-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Apnea-hypopnea index of less than 5 h-1 or greater than 30 h-1.&#xD;
&#xD;
          -  Predominance of central apneas and hypopneas, defined as more than 25% of all&#xD;
             respiratory events.&#xD;
&#xD;
          -  Professional drivers, risk profession or respiratory failure (according to criteria of&#xD;
             the clinical pathway for diagnosis and treatment of sleep-disordered breathing).&#xD;
&#xD;
          -  Very excessive daytime sleepiness (Epworth Sleepiness Scale&gt; 18).&#xD;
&#xD;
          -  Morbid obesity (BMI&gt; 40 kg / m2).&#xD;
&#xD;
          -  Prior treatment with CPAP.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Garcia-Rio, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario La Paz, IdiPAZ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Príncipe de Asturias</name>
      <address>
        <city>Alcalá de Henares</city>
        <state>Madrid</state>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 25, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario La Paz</investigator_affiliation>
    <investigator_full_name>Francisco Garcia-Rio</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

